Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAge Labs (BIOA) Short term Debt (2023 - 2026)

BioAge Labs' Short term Debt history spans 3 years, with the latest figure at $2.6 million for Q4 2025.

  • On a quarterly basis, Short term Debt fell 55.87% to $2.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.6 million, a 55.87% decrease, with the full-year FY2025 number at $2.6 million, down 55.87% from a year prior.
  • Short term Debt hit $2.6 million in Q4 2025 for BioAge Labs, down from $4.1 million in the prior quarter.
  • Over the last five years, Short term Debt for BIOA hit a ceiling of $6.0 million in Q4 2023 and a floor of $2.6 million in Q4 2025.
  • Historically, Short term Debt has averaged $5.2 million across 3 years, with a median of $6.0 million in 2023.
  • Biggest five-year swings in Short term Debt: changed 0.0% in 2024 and later plummeted 55.87% in 2025.
  • Tracing BIOA's Short term Debt over 3 years: stood at $6.0 million in 2023, then changed by 0.0% to $6.0 million in 2024, then plummeted by 55.87% to $2.6 million in 2025.
  • Business Quant data shows Short term Debt for BIOA at $2.6 million in Q4 2025, $4.1 million in Q3 2025, and $5.6 million in Q2 2025.